Organigram Global (OGI) Short-term Investments (2019 - 2026)
Organigram Global (OGI) posted quarterly Short-term Investments of -$36.2 million for Q1 2026, up 25.05% year-on-year from -$29.0 million in Q1 2025, and up 7.5% on a QoQ basis from -$39.1 million in Q4 2025.
Organigram Global (OGI) Short-term Investments (2019 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Short-term Investments for 6 consecutive years, with -$36.2 million the latest figure, recorded in Q1 2026.
- Quarterly Short-term Investments rose 25.05% year-over-year to -$36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.2 million (up 25.05% YoY) and the FY2025 annual result came in at -$39.1 million, changed N/A from the prior year.
- Short-term Investments rose to -$36.2 million in Q1 2026 per OGI's latest filing, from -$39.1 million in the prior quarter.
- Over the last five years, Short-term Investments for OGI reached as high as $600200.5 in Q3 2025 and fell as low as -$48.3 million in Q1 2025.
- A 3-year average of -$28.1 million and a median of -$36.2 million in 2026 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2025 — Short-term Investments plunged 124.22% — and 2026, when it rose 25.05%.
- Year by year, Short-term Investments stood at -$17.5 million in 2024, then tumbled by 124.22% to -$39.1 million in 2025, then increased by 7.5% to -$36.2 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered -$36.2 million, -$39.1 million, and $600200.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.21 Mn |
| Dec 31, 2025 | -39.14 Mn |
| Sep 30, 2025 | 600,200.51 |
| Mar 31, 2025 | -48.31 Mn |
| Dec 31, 2024 | -17.46 Mn |
| Nov 30, 2021 | 68.33 Mn |
| Aug 31, 2021 | 128.19 Mn |
| May 31, 2021 | 138.05 Mn |
| Feb 28, 2021 | 10.00 Mn |
| Nov 30, 2020 | 30.00 Mn |
| Aug 31, 2020 | 50.13 Mn |
| May 31, 2020 | 97,253.25 |
| Feb 29, 2020 | 153,000.00 |
| Aug 31, 2019 | 287,429.99 |